Sofinnova Partners orchestrated a transformative comeback for French biotech Abivax, beginning with a pivotal €12 million investment in 2019 during the company's financial distress. Recognizing the promise of Abivax's lead candidate obefazimod for ulcerative colitis, Sofinnova extended critical operational support, including appointing experienced CEO Marc de Garidel in 2023. This strategic partnership culminated in a positive Phase III readout, significantly boosting Abivax's valuation, and exemplifies how venture capital can pivot struggling biotechs towards success through targeted support and leadership changes.